Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | CuttingEdgeInfo Reports | Autoimmune Market Forecast to 2014 (TA223)

Autoimmune Market Forecast to 2014 (TA223)

Drive blockbuster revenue with autoimmune breakthroughs

The autoimmune market is proving that the era of the blockbuster is not dead.

Of 14 brands already at or expected to reach blockbuster status, half generate at least $3 billion annually. Nine mid-level products will generate $400 million, at minimum, by 2014. For autoimmune drugs, reaching blockbuster-level success is an expectation as much as a goal.

Whether you're exploring your options or need to increase your presence in the market, autoimmune compounds provide lucrative opportunities -- don't miss out!

From sales projections to clinical trial data to analysts' insights, Autoimmune Market Forecast to 2014 tells you everything you need to know. Unlike other market forecast reports out there, ours covers all of the major indications - rheumatoid arthritis, ulcerative colitis, Crohn's disease, multiple sclerosis, psoriasis and lupus - profiling 40+ drugs and nine leading autoimmune product manufacturers.

Delve into the data to:

* Learn how brands and drug classes have fared: where they've succeeded - and failed

* Show solid, objective evidence for your decision-making

* Keep track of the competition

* Get the latest on clinical trials

* Uncover potential business development opportunities

Companies Included in Report

The report analyzes autoimmune portfolios at nine companies that are successful in the autoimmune market. Each company profile examines strategies and identifies strengths and weaknesses.

* Abbott

* Roche

* Centacor (Johnson & Johnson)

* Biogen Idec

* Amgen

* Pfizer

* Schering-Plough (Merck)

* Merck KGaA

* Teva

Published: 2009

293 Pages

1000+ Metrics

43 Brands

9 Companies
Table of Contents
Price: $9,995.00 / €6,680.66

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions